Loading...
•
Jun 30, 2022
MannKind Q2 2022 Earnings Report
MannKind reported second quarter results, achieving multiple milestones including FDA approval for Tyvaso DPI and revenue generation from V-Go acquisition.
Key Takeaways
MannKind Corporation reported total revenues of $18.9 million for the second quarter of 2022. This includes Afrezza net revenue of $10.6 million, V-Go net revenue of $2.1 million, collaborations and services revenue of $5.9 million, and royalties of $0.3 million. The net loss for the quarter was $29.0 million, or $0.11 per share.
Tyvaso DPI approved by the FDA in May.
V-Go acquired May 31, contributing $2.1 million in net revenue for June.
Commercial Products Net Revenue reached $12.7 million, a 28% increase compared to Q2 2021.
Collaboration and Services Revenue was $5.9 million, up 171% compared to Q1 2022.
Revenue by Segment
Forward Guidance
No specific forward guidance was provided in the earnings report.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...